Histological examination in biopsy samples of responders showing endoscopic and histological healing at week (W)6/W12/W52 by vedolizumab (VDZ) or at W4–6 by infliximab (IFX) and their baseline (W0) samples
| Histological parameters | VDZ W0 (n=10) | VDZ W6 (n=3) | VDZ W12 (n=2) | VDZ W52 (n=7) | IFX W0 (n=5) | IFX W4–6 (n=5) |
|---|---|---|---|---|---|---|
| (1) Architectural changes (Geboes grade 0) | 0.1: n=3 (30%); 0.2: n=7 (70%) | 0.1: n=2 (66.7%); 0.2: n=1 (33.3%) | 0.2: n=2 (100%) | 0.0: n=1 (14.3%); 0.1: n=5 (71.4%); 0.2: n=1 (14.3%) | 0.1: n=1 (20%); 0.2: n=2 (40%); 0.3: n=2 (40%) | 0.1: n=2 (40%); 0.2: n=3 (60%) |
| (2) Mononuclear infiltrate (Geboes grade 1) | 1.1: n=2 (20%); 1.2: n=4 (40%); 1.3: n=4 (40%) | 1.0: n=1 (33.3%); 1.1: n=2 (66.7%) | 1.1: n=2 (100%) | 1.0: n=2 (28.6%); 1.1: n=5 (71.4%) | 1.2: n=1 (20%); 1.36: n=4 (80%) | 1.1: n=3 (60%); 1.2: n=2 (40%) |
| (3) CD3+ T lymphocytes | ↗↗↗ | ↗↗ | ↗↗ | ↗ | ↗↗↗ | ↗↗ |
| (4) CD4+/CD8+ T cells | Normal | Normal | Normal | Normal | Normal | Normal |
| (5) Mast cells in lamina propria | Normal | Normal | Normal | Normal | Normal | Normal |